or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    GILD A 0.12 5.15
    EXEL C 1.35 4.81
    INCY B 2.97 4.42
    RVMD B -0.40 4.36
    REGN D -0.41 4.16
    SRPT F -2.05 4.06
    ACLX C -2.48 3.78
    MRK F 1.04 3.47
    TWST D -3.94 2.94
    GERN D -2.86 2.49
    SWTX F 0.56 2.38
    IOVA F -0.43 2.32
    BEAM F -4.45 2.16
    LGND D 1.26 1.96
    NVAX D -2.45 1.82
    MRNA F -4.34 1.70
    BCRX D -2.89 1.68
    DVAX D 1.44 1.58
    NRIX D -1.69 1.48
    BPMC F -2.70 1.37
    CRSP F -2.98 0.94
    RCUS F 0.85 0.83
    VIR F 0.93 0.73
    IBRX F -3.23 0.67
    ARCT D 8.79 0.60
    FDMT F -3.70 0.53
    NTLA F -6.57 0.49
    OABI F -1.65 0.45
    EDIT F -4.11 0.32
    XNCR D -2.34 0.31
    DNA F -6.75 0.30
    QURE F -6.29 0.27
    MGNX F 4.26 0.20

    Represented by ETF Holdings

    Keywords: Biotechnology Biopharmaceutical Cancer Medicine Biology Life Sciences Immune System Infectious Diseases Antibodies Clinical Development Clinical Medicine Coronavirus Genetics Immunology Influenza Monoclonal Antibodies S&P 500 Cancer Treatment Enzymes Nasdaq 100
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for iShares Genomics Immunology and Healthcare ETF & its Holdings

    Date Stock Title
    Oct 1 GILD $1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
    Oct 1 ARCT Unveiling 3 Analyst Insights On Arcturus Therapeutics
    Oct 1 MRK U.S. port strike expected to have limited impact on healthcare supply chain: HHS
    Oct 1 MRNA The Covid Era Tech Promises To Reinvent Cancer Treatment
    Oct 1 SRPT Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
    Oct 1 ARCT ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
    Oct 1 MRNA ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
    Oct 1 MRNA Is Moderna, Inc. (MRNA) the Worst Performing Stock to Buy on the Dip?
    Oct 1 MRNA MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
    Oct 1 GERN High Growth Tech Stocks To Watch This October 2024
    Oct 1 MRNA Company News for Oct 1, 2024
    Oct 1 MRNA IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
    Oct 1 BCRX BioCryst Secures Major US Health Department Influenza Drug Deal
    Oct 1 NTLA Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
    Oct 1 BCRX BioCryst secures $69m contract from US to supply RAPIVAB for influenza
    Oct 1 MRK Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
    Oct 1 MRK Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
    Oct 1 GILD Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
    Oct 1 MRNA Moderna doses first subject in Phase III trial of mRNA norovirus vaccine in US
    Oct 1 MRNA Moderna, Cenra Healthcare enter JV to promote mRNA respiratory vaccine in Taiwan
    The investment seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
    Exchange Traded Fund Immunology Genomics
    Back to the Main IDNA Page...